Acute lymphoblastic leukemia in routine practice: A Turkish multicenter study

Amac: Son yillarda eriskinlerde akut lenfoblastik loseminin (ALL) tedavi yonetiminde onemli gelismeler meydana gelmistir. Bununla birlikte, ozellikle rutin uygulamada tedavi sonuclari hala tatmin edici degildir. Calismanin amaci, Turkiye’de birden fazla merkezde takip edilen genis bir ALL hasta grubunun genel klinik ozelliklerini, tedavi ozelliklerini ve sagkalim sonuclarini degerlendirmektir. Gerec ve Yontemler: Ocak 2003 ile Haziran 2017 tarihleri arasinda on farkli merkezdeki hematoloji kliniginde tani konulan ve farkli protokollerle tedavi edilen ALL hastalarinin verilerinin retrospektif analizi yapildi. Calismaya yaslari 17 ile 76 arasinda degisen toplam 288 hasta dahil edildi. Bu calismada ALL’li hastalar tedavi periyoduna, Philadelphia kromozom pozitifligine, tedavi protokolu ve allojenik hematopoetik kok hucre nakli (AHKHN) yapilip yapilmamasina gore siniflandirildi. Results: The majority of cases were B-cell in origin, while 224 patients had B-ALL and 64 of the patients had T-ALL. Median follow-up duration for all patients was 18.2 months (range: 0.03-161 months). Philadelphia chromosome positivity was determined in 49 patients (21.9%), and 54 patients (18.8%) were receiving allo-HSCT. After induction chemotherapy, 219 patients (76.0%) achieved complete remission, 32 patients (11.2%) were evaluated as treatment refractory, and 37 patients (12.8%) were deceased. Median overall survival was 47.7 months (95% confidence interval: 36.1-59.2) and median disease-free survival was 23.4 months (95% confidence interval: 6.7-40.0) for all patients. Conclusion: Multicenter studies are extremely important for defining the specific clinical features of a particular disease. The results of this study will make a significant contribution to the literature as they reflect real-life data providing valuable information about the Turkish ALL patient profile.